Author response: An open label trial of anakinra to prevent respiratory failure in COVID-19

Authors :: George N. Dalekos
Symeon Metallidis
Theodoros Marantos
Maria Dareioti
Evdoxia Kyriazopoulou
Nikolaos Vechlidis
Ioannis P Trontzas
Vasileios Petrakis
Aggelos Stefos
Mihai G. Netea
Areti Gravvani
Konstantinos N. Syrigos
Vassiliki Lygoura
Konstantina Katrini
L. Chatzis
Garyphallia Poulakou
Maria Saridaki
Nikolaos K. Gatselis
Danai Prasianaki
Karolina Akinosoglou
Jos W. M. van der Meer
Evangelos J. Giamarellos-Bourboulis
Stamatios Chalvatzis
Konstantinos Tsiakos
Georgia Loli
Eleni Karakike
Aliki Stamou
Theologia Gkavogianni
Miltiades Kyprianou
Periklis Panagopoulos
Dimitra-Melia Myrodia
Stamatios Chatzis
Haralampos J. Milionis
Maria Kosmidou
Jesper Eugen-Olsen
Christina Avgoustou
Olga Tsachouridou
Ilias Papanikolaou
Sarah P. Georgiadou
Publication Year :: 2021
Publisher :: eLife Sciences Publications, Ltd, 2021.

Subjects :: medicine.medical_specialty
Anakinra
Coronavirus disease 2019 (COVID-19)
Respiratory failure
business.industry
medicine
Open label
Intensive care medicine
business
medicine.drug

Full Text Access

Tools